Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Scleroderma, Systemic: early-phase trial registry
1 of 7 indexed Scleroderma, Systemic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Scleroderma, Systemic: 7 US clinical trials tracked, 1 recruiting.
Scleroderma, Systemic is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Stanford University, running 2 of these trials.
Enrollment posture brief
Registry condition scleroderma-systemic
OPEN 1 | RECR 14% | LATE 0 | EARLY 4 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Scleroderma, Systemic lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Scleroderma, Systemic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Scleroderma, Systemic is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Scleroderma, Systemic research.
Stanford University accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Scleroderma, Systemic trials plan to enrol fewer than 100 people.
Median target enrolment is 34 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.
-
Scleroderma, Systemic research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
GlaxoSmithKline
NCT05878717
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Cumberland Pharmaceuticals
NCT02682511
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
University of Utah
NCT04922736
Study of Silicone-Associated Connective Tissue Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00001330
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Michael Roth
NCT03221257
A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
Stanford University
NCT00725361
Imatinib in Systemic Sclerosis
Stanford University
NCT00506831
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Scleroderma, Systemic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Scleroderma, Systemic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Scleroderma, Systemic page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Scleroderma, Systemic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stanford University sponsors the most Scleroderma, Systemic trials on record, review their full trial history before evaluating a specific study. See Stanford University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Scleroderma, Systemic condition card totals 7 registered trials; most-linked intervention Placebo (Plac); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.